Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Infect Dis. 2011 Jul;11(7):557-70. doi: 10.1016/S1473-3099(11)70007-X. Epub 2011 May 18.

Rationale for pertussis booster vaccination throughout life in Europe.

Author information

1
Department of Paediatrics and Adolescent Medicine, University Medical Centre, Johannes Gutenberg University, Mainz, Germany. zepp@kinder.klinik.uni-mainz.de

Abstract

Although the introduction of universal pertussis immunisation in infants has greatly reduced the number of reported cases in infants and young children, disease incidence has been increasing in adolescents and adults in recent years. This changing epidemiological pattern is probably largely attributable to waning immunity after natural infection or vaccination. Furthermore, improved diagnostic testing, active surveillance, changes in disease susceptibility, vaccine characteristics, and increased awareness of the disease might also be contributing factors. Susceptibility to pertussis in adolescents and adults results not only in direct morbidity in these age groups, but also poses a transmission risk to susceptible non-immune infants who are often too young to be vaccinated. Because vaccination schedules vary across Europe, we review the pertussis situation in this region and propose considerations for use of pertussis booster vaccinations at different ages to reduce individual morbidity and transmission from present rates and increase herd protection.

PMID:
21600850
DOI:
10.1016/S1473-3099(11)70007-X
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center